title: Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.
abstract: The effect of muramyl tripeptide (MTP-PE) encapsulated in liposomes (multilamellar vesicles, MLV) on hemopoiesis and hemopoietic recovery after sublethal single irradiation with a dose of 6 Gy was investigated. MTP-PE/MLV during 24 h after administration stimulated the monocyte/macrophage system and accelerated recovery from radiation-induced damage of hemopoiesis. The above reparative processes were accompanied by hyperplasia of granulocytes in the bone marrow on days 6-8 after irradiation, acceleration of erythropoiesis in the spleen and recovery of granulocyte count in the peripheral blood. The repair of thymic and splenic lymphoid tissues as well as recovery of the number of mononuclear cells in peripheral blood was not influenced by MTP-PE/MLV application.
authors.affiliation: Department of Cellular and Molecular Biology, Faculty of Science, P.J. Safárik University, Kosice, Slovakia.
authors.forename: N O
authors.initials: NO
authors.lastname: Macková
authors.forename: P
authors.initials: P
authors.lastname: Fedorocko
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004337:Drug Carriers; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects* / Q000528:radiation effects; D007274:Injections, Intraperitoneal; D007958:Leukocyte Count / Q000187:drug effects; D008081:Liposomes; D051379:Mice; D008810:Mice, Inbred C57BL; D009929:Organ Size / Q000187:drug effects; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011833:Radiation Injuries, Experimental / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013950:Thymus Gland / Q000166:cytology / Q000187:drug effects; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D010714:Phosphatidylethanolamines; D011837:Radiation-Protective Agents; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine